Welcome to the Polio Partners Group Meeting 28 April 2021 from 15:00-17:30 CET



As you join the meeting

- Please ensure you are <u>muted</u> unless speaking to avoid background noise
- So that we know who is who, please make sure your name follows the

'ORGANIZATION / FIRST NAME LAST NAME' naming convention.

 To change your name, click on the "Participants" button at the top of the Zoom window.



- Next, hover your mouse over your name in the "Participants" list on the right side of the Zoom window. Click "Rename."
- Enter your 'ORGANIZATION / FIRST NAME LAST NAME' (e.g., "WHO / John Doe") and click "OK."

During the meeting

Use the chat feature to ask
 questions and communicate with your
 fellow participants. You can make your
 questions "to everyone" or send them
 privately to the Moderator.



Q&A

- Use the raise your hand button, if you'd like to ask a question
 - Click on the icon labelled "Participants" at the bottom centre of your screen
 - At the bottom of the window on the right side of the screen, click the button labelled "Raise hand"
 - If you want to lower your hand, lower it by clicking on the same button, now labelled "Lower hand"



Polio Partners Group Meeting Agenda



(all times in Central European Time)

15:00 – 15:10: Welcome and introductory remarks (PPG Co-Chairs) – *10 minutes*

15:10 – 15:30: Update on key Polio Oversight Board decisions (Michael McGovern) – *20 minutes*

15:30 – 16:10: Discussion – *40 minutes*

16:10 – 16:20: Health break – *10 minutes*

16:20 – 16:40: Programmatic and strategic updates (Aidan O'Leary) – 20 minutes

16:40 – 16:50: Programmatic and strategic updates (Sir Liam Donaldson) – *10 minutes*

16:50 – 17:20: Discussion – *30 minutes*

17:20 – 17:30: Closure of meeting (PPG Co-Chairs) – *10 minutes*





Presentations







BILL & MELINDA GATES foundation

CENTERS FOR DISEASE CONTROL AND PREVENTION



Dr. Christopher J. Elias, POB Chair and BMGF President of Global Development

Dr. Rochelle P. Walensky Director of the US CDC Dr. Seth F. Berkley
CEO of GAVI, The Vaccine
Alliance







Mr. Michael K. McGovern Chair of Rotary International PolioPlus Committee Ms. Henrietta H. Fore Executive Director of UNICEF

Dr. Tedros Adhanom Ghebreyesus Director General of WHO




Strategy Revision due to Program Setbacks

- Comprehensive process began in July 2020
- 300+ stakeholders (GPEI reps, donors, polio-affected countries, technical advisors, external stakeholder panel, etc.)
- Eight working groups





Polio Eradication Strategy 2022-2026





Shifts in new strategy



Re-establish polio eradication as a public health emergency

- Hold governments, agencies and global partners accountable for progress
- Improve community engagement by addressing their needs and including their voices, and capabilities

 Balance capacity and decision-making between HQ and regional and country teams



GOAL 1: Permanently interrupt all poliovirus in endemic countries

GOAL 2: Stop cVPDV transmission, prevent outbreaks in polio-free regions

5 Strategic Objectives



Political advocacy to increase government ownership



Community engagement to drive demand for vaccination



Improve polio immunization campaigns to increase quality



Integrate with other health programs to reach more children



Expand surveillance for polio and other vaccine preventable disease





TIMELINE: Goals 1 & 2

	2021	2022	2023	2024	2025	2026
Goal 1: Endemic Countries	Begin implementing program improvements	Transmission limited to core reservoirs	Interruption of WPV1 and cVDPV2	Plan for polio transition	Continue polio transition planning	Certify eradication of WPV1 and validate absence of cVDPV2
Goal 2: Outbreak Countries	nOPV2 initial use	Phase out mOPV2	Report last isolate of cVPDV2 2nd dose of IPV introduced in routine immunization		Anticipated nOPV1 and 3	Validate absence of cVDPV2 Anticipated trivalent nOPV



Budget requirements 2022-2026

Estimated cost: US\$5.3 billion

Main cost drivers:

- surveillance
- outbreak response and preventive campaigns
- integrated health services
- vaccine supply
- staffing





Other Major Developments

Governance Review:

- Donor representation on Polio Oversight Board, Financial Accountability Committee, Strategy Committee
- Increased engagement of the Polio Oversight Board
- Focus on Integration


Management Review:

- Reorganization of the GPEI structure
- Monitoring and Evaluation Framework, including key performance indicators, to monitor progress
- Increased focus on countries and regions





GPEI Management Structure



Global Advisory & Consultative Support

Provide independent external feedback & technical support on key strategic issues

> Independent Monitoring Board

mOPV2 Advisory Group

SAGE Policy Working Group

Global Certification Commission

Polio Partners Group







Thank you!

